EASL - AASLD SPECIAL CONFERENCE
NEW PERSPECTIVES IN HEPATITIS C VIRUS INFECTION - THE ROADMAP FOR CURE
23-24 September 2016
Paris, France
Organising Committee:
Thomas Berg, Germany
Raymond Chung, United States
Xavier Forns, Spain
Norah Terrault, United States

DAY 1 – Friday 23 September 2016

08:00 – 08:10 Welcome and Introduction
Thomas Berg, Germany
Raymond Chung, United States
Xavier Forns, Spain
Norah Terrault, United States

Session 1: EPIDEMIOLOGY OF HCV: Today and Tomorrow (past – present – future)
Chair: Massimo Colombo, Italy
John Ward, United States,

08:10 – 08:30 Phylogeny and molecular evolution of HCV - History of the HCV epidemics
Peter Simmonds, United Kingdom

08:30 – 08:50 The global HCV epidemiology
John Ward, United States

08:50 – 09:10 Current epidemiology in high risk populations and the risk of reinfection
Gregory Dore, Australia

09:10 – 09:30 Predicting the future HCV epidemiology
TBC

09:30 – 09:50 Q & A

09:50 – 10:30 ePoster Session 1 and coffee break

Session 2: VIROLOGY AND PATHOGENESIS
Chair: Thomas Baumert, France
Raymond Chung, United States
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>10:30 – 11:00</td>
<td>State of the Art: From HCV discovery towards vaccine strategies</td>
<td>TBD</td>
</tr>
<tr>
<td>11:00 – 11:20</td>
<td>Host – viral interactions and the role of genetics</td>
<td>Raymond Chung, United States</td>
</tr>
<tr>
<td>11:20 – 11:40</td>
<td>Immune pathogenesis of acute and chronic HCV infection</td>
<td>Robert Thimme, Germany</td>
</tr>
<tr>
<td>11:40 – 12:00</td>
<td>HCV and metabolism</td>
<td>Francesco Negro, Switzerland</td>
</tr>
<tr>
<td>12:00 – 12:20</td>
<td>Pathogenesis of HCV-induced HCC</td>
<td>Yujin Hoshida, United States</td>
</tr>
<tr>
<td>12:20 – 12:40</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>12:40 – 14:00</td>
<td>ePoster Session 2&amp;3 and lunch</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 3: LONG-TERM CONSEQUENCES</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Geoff Dusheiko, United Kingdom</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Zobair Younossi, United States</td>
<td></td>
</tr>
<tr>
<td>14:00 – 14:20</td>
<td>Natural history of HCV infection - Predicting disease progression</td>
<td>Andrew Muir, United States</td>
</tr>
<tr>
<td>14:20 – 14:40</td>
<td>How SVR impacts hepatic and extrahepatic disease outcomes</td>
<td>Zobair Younossi, United States</td>
</tr>
<tr>
<td>14:40 – 15:10</td>
<td>The point of no return: long-term risks despite HCV eradication</td>
<td>Antonio Craxi, Italy</td>
</tr>
<tr>
<td></td>
<td>- The clinician perspective</td>
<td>Pierre Bedossa, France</td>
</tr>
<tr>
<td>15:10 – 15:40</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>15:40 – 16:10</td>
<td>ePoster Session 4 and coffee break</td>
<td></td>
</tr>
<tr>
<td></td>
<td><strong>Session 4: ASSESSMENT OF HCV DISEASE</strong></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Chair: Thomas Berg, Germany</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Guadalupe Garcia Tsao, United States</td>
<td></td>
</tr>
<tr>
<td>16:10 – 16:30</td>
<td>Staging of fibrosis in 2016 – are non-invasive tests enough?</td>
<td>Laurent Castera, France</td>
</tr>
<tr>
<td>16:30 – 16:50</td>
<td>The role of liver biopsy and HVPG measurement in the DAA era</td>
<td>Guadalupe Garcia Tsao, United States</td>
</tr>
<tr>
<td>16:50 – 17:10</td>
<td>Importance of baseline resistance and viral chimera</td>
<td>Christoph Sarrazin, Germany</td>
</tr>
<tr>
<td>17:10 – 17:30</td>
<td>Next generation diagnostic tools – ready to use?</td>
<td>Jean-Michel Pawlotsky, France</td>
</tr>
<tr>
<td>17:30 – 17:50</td>
<td>Q &amp; A</td>
<td></td>
</tr>
<tr>
<td>17:50 – 18:20</td>
<td>ePoster Session 5</td>
<td></td>
</tr>
</tbody>
</table>
DAY 2 – Saturday 24 September 2016

Session 5: TREATMENT OF HCV
Chair: Xavier Forns, Spain
Nezam Afdhal, United States

08:00 – 08:30  State of the Art: From the replicon system to the development of DAAs
Raffaele De Francesco, Italy
08:30 – 08:50  Management of acute hepatitis C
Heiner Wedemeyer, Germany

The treatment approach according to HCV genotype
08:50 – 09:10  The treatment approach for a patient with HCV type 1
Nezam Afdhal, United States
09:10 – 09:30  The treatment approach for a patient with HCV type 2
Alessandra Mangia, Italy
09:30 – 09:50  The treatment approach for a patient with HCV type 3
Maria Buti, Spain
09:50 – 10:10  The treatment approach for a patient with HCV types 4-6
Imam Waked, Egypt

10:10 – 10:30  Q & A

10:30 – 11:00  ePoster Session 6 and coffee break

Session 6: REMAINING CHALLENGES IN THE TREATMENT OF HCV
Chair: Didier Samuel, France
Norah Terrault, United States

HCV treatment in the liver transplant setting
11:00 – 11:20  Treating the patient with decompensated disease and on the waiting list
Greg Everson, United States
11:20 – 11:40  Treating the post-transplant patient
Xavier Forns, Spain

How to manage your patient with…
11:40 – 12:00  Kidney failure
Stanislas Pol, France
12:00 – 12:20  HCV-HIV co-infection
Susanna Naggie, United States
12:20 – 12:40  DAA failure
Stefan Zeuzem, Germany

12:40 – 13:00  Q & A

13:00 – 14:00  ePoster Session 7&8 and lunch
Session 7: ROADMAP TO CURE
Chair: Alessio Aghemo, Italy
Greg Dore, Australia
14:00 – 14:20 Increasing treatment rate: strategies for a country and risk-adapted screening approach
   Jordan Feld, Canada
14:20 – 14:40 Roadmap to cure – the patients’ view
   Achim Kautz, Belgium
14:40 – 15:00 Roadmap to cure – the population-based view
   David Thomas, United States
15:00 – 15:20 Roadblock to cure
   TBD

15:20 – 16:00 Round table discussion: Access to treatment in 2016
   Panelists: Marc Bourlière, France; Graham Foster, United Kingdom, Andrew Muir, United States & David Nelson, United States

16:00 – 16:30 ePoster Session 9 and coffee break

Session 8: HCV TREATMENTS PERSPECTIVES
Chair: Patrick Marcellin, France
David Nelson, United States
16:30 – 16:50 Next generation DAAs - how short can we go?
   David Nelson, United States
16:50 – 17:10 Entry inhibitors and other host-targeted antiviral strategies
   Thomas Baumert, France
17:10 – 17:30 Future perspectives and unresolved issues
   Michael Manns, Germany

17:30 – 17:50 Q & A

17:50 – 18:00 Concluding remarks
   Thomas Berg, Germany
   Raymond Chung, United States
   Xavier Forns, Spain
   Norah Terrault, United States